Navigation Links
GenVec Announces Research on Improved Vaccine Vectors
Date:4/6/2012

GAITHERSBURG, Md., April 6, 2012 /PRNewswire/ -- GenVec, Inc. (NASDAQ:   GNVC) announced publication of research on GenVec's new vaccine vectors. These vectors circumvent neutralizing antibodies in order to generate the desired immunologic response. The paper has been published online in PloS ONE, and can be accessed at http://dx.plos.org/10.1371/journal.pone.0033920. The article titled "Modification of Ad5 Hexon Hypervariable Regions Circumvents Pre-existing Ad5 Neutralizing Antibodies and Induces Protective Immune Responses" is an example of GenVec's proprietary vaccine technology.

"This paper describes one of several new tools we are using to generate better vaccines," noted Douglas E. Brough, Ph.D., GenVec's Vice President of Research.  "This approach alters key elements of the vector so that a good vaccine response is generated even if an individual was previously exposed to an adenovirus.  This technology expands our genetic vaccine toolbox used to create superior vaccines."

About GenVec

GenVec is a biopharmaceutical company using differentiated, proprietary technologies to create superior therapeutics and vaccines. A key component of our strategy is to develop and commercialize our product candidates through collaborations. GenVec is working with leading companies and organizations such as Novartis, Merial, and the U.S. Government to support a portfolio of product programs that address the prevention and treatment of a number of significant human and animal health concerns. GenVec's development programs address therapeutic areas such as hearing loss and balance disorders; as well as vaccines against infectious diseases including respiratory syncytial virus (RSV), herpes simplex virus (HSV), dengue fever, malaria, and human immunodeficiency virus (HIV). In the area of animal health we are developing vaccines against foot-and-mouth disease (F
'/>"/>

SOURCE GenVec, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
2. GenVec Expands Contract Supporting Malaria Vaccine Program
3. GenVec Reports Second Quarter 2009 Financial Results
4. GenVec Receives an Approximately $2.5 Million Grant to Support Novel Cell Line Development
5. GenVec Announces Registered Offering of $6 Million in Common Stock and Warrants
6. GenVec Announces Third Quarter 2009 Results Conference Call
7. GenVec Reports Third Quarter 2009 Financial Results
8. Merriman Curhan Ford Acted as Placement Agent in GenVecs $28 Million Registered Offering
9. GenVec to Present at the 13th Annual BIO CEO & Investor Conference
10. GenVec To Host Fourth Quarter and Year-End 2010 Earnings Call and Webcast
11. GenVec, Inc. Announces Effectiveness of Reverse Stock Split
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... IRVINE, Calif. (PRWEB) August 19, 2014 ... Indiegogo campaign to raise $200,000 to fund a ... diagnostic device. , This development is a ... one-size-fits-all model of care to the implementation of ... patient-centric method of practicing medicine. , Indiegogo contributions ...
(Date:8/19/2014)... CSSi, the leader in patient recruitment solutions ... of the company,s Medical and Clinical Advisory Board ("MCAB") ... William E. Gannon, Jr. to the MCAB. ... The MCAB, with Dr. Gannon,s leadership, will help ... set strategic goals for the advancement and development of ...
(Date:8/18/2014)... August 19, 2014 2014 Deep ... is a professional and in-depth research report on ... Linalool information, including its definition, classification, application, ... overview. This research covers the international market analysis, ... industry analysis covering macroeconomic environment & economic situation ...
(Date:8/18/2014)... and data storage may someday run on ... to read and write digital information, outperforming ... But ferroelectrics must first overcome a few ... of "forgetting" stored data. , Now, ... Brookhaven National Laboratory have discovered nanoscale asymmetries ...
Breaking Biology Technology:Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 2Cellgen Diagnostics Launches Indiegogo Crowdfunding Campaign for DNA Medical Testing Device 3CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 2Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 3Linalool Industry & Diphenylamine Market (Global, China) 2014 Analysis Now Available at DeepResearchReports.com 4Promising ferroelectric materials suffer from unexpected electric polarizations 2Promising ferroelectric materials suffer from unexpected electric polarizations 3Promising ferroelectric materials suffer from unexpected electric polarizations 4
... Inc. (OTC/BB: GNBP), a biotechnology company developing targeted cancer ... its Board of Directors.  Mr. Voyticky is currently President ... an oil and gas exploration company, and has more ... merger and acquisition consulting. The Genesis Biopharma Board now ...
... WOODLANDS, Texas, July 18, 2011 One of the ... to achieve Meaningful Use requirements in the coming years. ... learning more about Meaningful Use requirements and how these ... a free webinar at 1 p.m. EDT (10 a.m. ...
... 90% , Reduction in HIV ... SEEK, a privately owned biopharmaceutical company specializing,in ... of its HIV-v vaccine which demonstrates a one,log (approx ... placebo group, after just a single vaccine,injection. Gregory Stoloff, ...
Cached Biology Technology:Genesis Biopharma Names David Voyticky to Board of Directors 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 2Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 2SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 3SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 4SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 5SEEK Announces Clinical Proof of Efficacy in HIV Vaccine Phase Ib/II Human Trial 6
(Date:8/19/2014)... , August 19, 2014 Smart ... Digital Wallet Choices as latest developments, ad campaigns and ... (NASDAQ: EBAY ), Amazon.com Inc. (NASDAQ: ... ), Google Inc. (NASDAQ: GOOG ) and ... NXTD) a biometric authentication company focused on the growing ...
(Date:8/19/2014)... protect their young have bigger brains than counterparts that ... British Columbia study. , Stickleback fish are well known ... male of the species, rather than the female, cares ... females and researchers wanted to find out if the ... caregivers. , In the study, published recently in ...
(Date:8/18/2014)... major Arizona watershed may lose access to important segments ... is reduced by the effects of climate warming, new ... in the Verde River Basin, are already threatened or ... resources throughout the river and its tributary streams. The ... (Gila robusta) and Sonora sucker (Catostomus insignis). , A ...
Breaking Biology News(10 mins):Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 2Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 3Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 4Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 5Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 6Digital Wallet Choices; PayPal, Google Wallet, Apple Passbook - and Now Wocket Smart Wallet : Who Addresses Issues of Security? 7Climate change will threaten fish by drying out Southwest US streams, study predicts 2Climate change will threaten fish by drying out Southwest US streams, study predicts 3
... at Johns Hopkins have discovered how to block a molecular ... oxygen during a stroke. The Hopkins study, conducted on mice, ... protein on the surface of nerve cells called the EP1 ... as ONO-8713, turns it off. , The finding ...
... garden compost to forest greenery, the mold Aspergillus fumigatus ... its impact. The most common mold causing infection, A. ... among people with weakened immune systems. , Now, in ... scientists at The Institute for Genomic Research (TIGR) and their ...
... Chinese men are selectively switching from traditional Chinese ... but sticking with tradition for ailments such as ... published in Environmental Conservation. , The finding supports ... at the advent of Viagra's commercial release in ...
Cached Biology News:Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 2Blocking the nerve receptor EP1 in mouse models reduces brain damage caused by stroke 3Breaking the mold: Research teams sequence three fungus genomes 2Viagra's hidden help for wildlife 2
... Features hardwall acrylic panels mounted ... to form a free-standing modular ... Class 10/ISO 3. Optional ceiling ... ionizers are configured to customer ...
...
... This modular benchtop fume hood ... allowing safe indoor release of ... most organic contaminants. Configurations are ... flow; options include final HEPA ...
...
Biology Products: